Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Medicenna Therapeutics Corp
T.MDNA
Alternate Symbol(s):
MDNAF
Healthcare
Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior...
CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:MDNA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Next
(98)
•••
windymayor1
X
View Profile
View Bullboard History
Comment by
windymayor1
on Sep 29, 2022 10:17am
RE:RE:Shouldn't this company be multiple dollars ?
Bloom Burton maintains their $9.00 US target after yesterday's news. States "They remain bullish with results being incremental and mixed. MDNA 11 appears substantially safer than Proleukin
...more
(98)
•••
windymayor1
X
View Profile
View Bullboard History
Comment by
windymayor1
on Sep 28, 2022 10:09pm
RE:Shouldn't this company be multiple dollars ?
Definitely. What's this worth to Merck!??
CLOUD DX Signs Multi-Year Contract with Provincial Health Authority
posted May 07, 2024 9:00am by
Cloud DX Inc.
-
|
The company is pleased to announce the execution on April 23, 2024 of a Remote Patient Monitoring Agreement for Cloud DX RPM Services with a Canadian Provincial Health Authority. This agreement is the 4th Provincial Health Authority contract for Cloud DX remote patient monitoring (RPM) services, alongside Alberta, the Yukon and Prince Edward Island. The contract has a term of 36 months with 2 extensions of 12 months each. The average contract value of each individual subscription is expected to be approximately ...read more
(229)
•••
Galaxym31
X
View Profile
View Bullboard History
Post by
Galaxym31
on Sep 28, 2022 2:27pm
Shouldn't this company be multiple dollars ?
$$$
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 28, 2022 9:25am
New Press Release - Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11's Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY Study
Confirmed partial response in fourth-line metastatic pancreatic cancer patient, who had previously failed chemotherapy and checkpoint inhibitor therapy, supports MDNA11’s single-agent potential in advanced solid tumors unresponsive to established treatments The observed tumor control rate of...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 22, 2022 7:30am
New Press Release - Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022
-- Single agent Anti-PD1-IL-2 BiSKIT™ showed superior efficacy compared to a combination of an anti-PD1 antibody with an IL-2 Superkine in murine models of colon, skin, and breast cancer --IL-4/IL-13 Super-antagonist displayed monotherapy activity in multiple cancer models and in synergy with...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 21, 2022 5:00pm
New Press Release - Medicenna Announces Results of Annual Meeting of Shareholders
TORONTO and HOUSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the voting results from the Company’s annual meeting of shareholders held today, September 21...
read article.
(98)
•••
windymayor1
X
View Profile
View Bullboard History
Comment by
windymayor1
on Sep 13, 2022 6:06pm
RE:How is this not amazing news ? What am I missing please
Well firstly I would have halted the stock as I think this is material. Then offer a bit more details of the collaberation. what costs are paid by whom etc. Then have a comment from the Merck'
...more
(463)
•••
TrevorAbes
X
View Profile
View Bullboard History
Post by
TrevorAbes
on Sep 13, 2022 5:40pm
MDNA announces clinical collaboration with Merck
https://themarketherald.ca/medicenna-announces-clinical-collaboration-with-merck-to-evaluate-mdna11-in-combination-with-keytruda-pembrolizumab-in-ability-trial-2022-09-13/
(229)
•••
Galaxym31
X
View Profile
View Bullboard History
Post by
Galaxym31
on Sep 13, 2022 11:27am
How is this not amazing news ? What am I missing please
anyone ?
(229)
•••
Galaxym31
X
View Profile
View Bullboard History
Post by
Galaxym31
on Sep 13, 2022 11:00am
Million traded on US side .
$$$
(229)
•••
Galaxym31
X
View Profile
View Bullboard History
Comment by
Galaxym31
on Sep 13, 2022 10:59am
RE:RE:Medicenna Announces Clinical Collaboration with Merck
Agree.
(98)
•••
windymayor1
X
View Profile
View Bullboard History
Comment by
windymayor1
on Sep 13, 2022 9:43am
RE:Medicenna Announces Clinical Collaboration with Merck
This is big news! MDNA should have halted the stock? Mkt reaction is nil.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 08, 2022 7:30am
New Press Release - Medicenna to Present at Investor and Scientific Conferences in September
TORONTO and HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that the Company management and scientific teams will present at the following investor and...
read article.
(463)
•••
TrevorAbes
X
View Profile
View Bullboard History
Post by
TrevorAbes
on Aug 09, 2022 5:14pm
MDNA prices US$20 million public offering
https://themarketherald.ca/medicenna-tsxmdna-prices-us20-million-public-offering-2022-08-09/
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
NOI Filed for Drill Program at Lithium/Uranium Project in Nevada
Silvercorp to Acquire Adventus for Implied Consideration of C$0.50 per Share
Meet one of the Strongest Contenders to Lead Canada’s Cannabis Market
Multiple High-Grade Gold Hits at the Tonopah Gold Project Including 90 Meters at 2.0 gpt Gold
A Leading Provider in Virtual Healthcare Adds 4th Provincial Health Authority Contract